In this second patient case video from BREAST CANCER CONNECT, Prof. Maria Vittoria Dieci delves into the continuation of a patient case with ER+/HER2- metastatic breast cancer initially presented in our first video of this series.

Throughout this journey, we'll explore what to expect after prescribing elacestrant and take a closer look at patient-reported outcomes in the EMERALD trial.

Catch up on the first video to hear Prof Francois-Clement Bidard discuss how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • PROs results demonstrating no difference between treatment arms in the EMERALD trial, support elacestrant as a clinically meaningful option in this setting

  • Elacestrant has a manageable safety profile

  • If a patient progresses on elacestrant, the choice of subsequent therapy line should be based on multiple factors, including sensitivity to prior treatments, disease burden, and tumour biology. In this context, ADCs represent a new option

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Maria Vittoria Dieci, MD, is Associate Professor at the University of Padova, vice-director of the Specialization School in Medical Oncology at the same University and attending physician at the Division of Oncology 2 of the Istituto Oncologico Veneto in Padova. She specialised in Oncology in March 2012 at the University of Modena. From May 2012 to November 2013 she completed a 18-month-research experience at the Translational Research Unit (INSERM U981) of the Gustave Roussy Institute (Villejuif, France), and obtained the “Diplome Universitaire Européen en Recherche Translationnelle et Clinique en Cancérologie”. Since November 2013 she has been conducting research and clinical activity in the field of breast cancer at the University of Padova / Istituto Oncologico Veneto IRCCS.

She is panelist of the Breast Cancer Guidelines by the Italian Association of Medical Oncology. Prof Dieci’s research production from 2008 up till now consists of more than 140 papers in peer-reviewed journals.

Prof. Maria Vittoria Dieci has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Pfizer, Novartis, Roche, Exact Science, Daiichi Sankyo, Gilead, Seagen.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Clinical insights and expert discussion

Experts
Prof. Domenica Lorusso, Prof. Jean-Sebastien Frenel
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2026

This programme has been sponsored by PMV Pharma and is intended for HCPs only.
publication Scientific Publication
Oncology 
ADCs in HER2+ metastatic breast cancer and management of adverse events

Consensus-based guidance for clinicians and patients

Experts
Prof. Javier Cortés, Prof. Giuseppe Curigliano, Prof. Shaheenah Dawood, Dr Grażyna Suchodolska, Dr Sara Tolaney, Carla Whitbread
Endorsed by
EONS - European Oncology Nursing Society Europa Donna
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Feb 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
expert-video-animation Animated Video
Oncology Obstetrics and Gynecology 
Understanding HER2 testing in gynecological cancers

Best practices and treatment implications

Experts
Prof. Fernando A. Soares
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Feb 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo.
symposium Masterclass / SymposiumVideo overview
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from the APBCS 2026 Satellite Symposium

Experts discuss 2L+ treatment strategies in endocrine therapy-eligible patients

Experts
Dr Mastura Md Yusof, Dr Hope S. Rugo, Prof. Matteo Lambertini
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jan 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs only 
podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca